z-logo
Premium
Multi‐center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era
Author(s) -
Karmali Reem,
Switchenko Jeffrey M.,
Goyal Subir,
Shanmugasundaram Krithika,
Churnetski Michael C.,
Kolla Bhaskar,
Bachanova Veronika,
Gerson James N.,
Barta Stefan K.,
Gordon Max J.,
Danilov Alexey V.,
Grover Natalie S.,
Epperla Narendranath,
Mathews Stephanie,
Burkart Madelyn,
Sawalha Yazeed,
Hill Brian T.,
Ghosh Nilanjan,
Park Steven I.,
Bond David A.,
Maddocks Kami J.,
Badar Talha,
Fenske Timothy S.,
Hamadani Mehdi,
Guo Jin,
Malecek Mary,
Kahl Brad S.,
Martin Peter,
Blum Kristie A.,
Flowers Christopher R.,
Cohen Jonathon B.
Publication year - 2021
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.26306
Subject(s) - rituximab , medicine , univariate analysis , mantle cell lymphoma , cytarabine , multivariate analysis , survival analysis , lymphoma , oncology , surgery , chemotherapy
Clinical outcomes and predictors of survival in patients with newly diagnosed mantle cell lymphoma (MCL) treated in the rituximab era (2000–2015) at 12 US academic centers were assessed to identify determinants of survival across age groups. Objectives were to characterize and compare practice patterns, outcomes and prognostic factors for survival in younger patients (age < 65) and older patients (age ≥ 65 years). Among 1162 patients included, 697 were younger and 465 were older. In younger patients, 2‐year progression free survival (PFS) and overall survival (OS) rates were 79% and 92% respectively; blastoid histology, ECOG ≥ 2, and lack of maintenance rituximab (MR) remained statistically relevant to poor OS on univariate analysis (UVA) and multivariate analysis (MVA). In older patients, 2‐year PFS and OS rates were 67% and 86% respectively; lack of maintenance rituximab remained significantly associated with inferior PFS and OS on UVA and MVA ( p  < 0.001). Two‐year PFS rates were 79%, and 67% and 2‐year OS rates were 92% and 86% for ages < 65 and ≥ 65 respectively ( p  < 0.001). First‐line high‐dose cytarabine exposure and/or MR lessened the negative impact of age on survival. Taken collectively, survival outcomes for older patients remain inferior to those of younger patients in the rituximab era. However, maintenance rituximab and potentially high‐dose cytarabine‐based induction can mitigate the negative impact of age on survival.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here